无容量
依维莫司
肾细胞癌
医学
肿瘤科
内科学
癌
泌尿科
免疫疗法
癌症
作者
Robert J. Motzer,Bernard Escudier,Ray McDermott,Saby George,Hans J. Hammers,Sandhya Srinivas,Scott S. Tykodi,Jeffrey A. Sosman,Giuseppe Procopio,Elizabeth R. Plimack,Daniel Castellano,Toni K. Choueiri,Howard Gurney,Frede Donskov,Petri Bono,John Wagstaff,Thomas Gauler,Takeshi Ueda,Yoshihiko Tomita,Fabio A.B. Schutz
标识
DOI：10.1056/nejmoa1510665
摘要
Nivolumab, a programmed death 1 (PD-1) checkpoint inhibitor, was associated with encouraging overall survival in uncontrolled studies involving previously treated patients with advanced renal-cell carcinoma. This randomized, open-label, phase 3 study compared nivolumab with everolimus in patients with renal-cell carcinoma who had received previous treatment.
科研通智能强力驱动
Strongly Powered by AbleSci AI
cdercder
无语的安白
个性归尘
小茄子爷爷
OCDer
可千万不要躺平呀
shinysparrow
挖掘机
andrele
斯寜
scm
hjyylab
轻松小张
过氧化氢
wangrblzu
coolkid
YifanWang
昏睡的蟠桃
jyy
典雅问寒
皖公网安备34019202002308
